Mitra opens U.S. branch to focus on cardiology nicheCanadian PACS software developer Mitra Imaging has launched a U.S. company to develop cardiology image and information management products. The new company, based in Hartland, WI, will promote
Canadian PACS software developer Mitra Imaging has launched a U.S. company to develop cardiology image and information management products. The new company, based in Hartland, WI, will promote and adapt Mitra's PACS Broker connectivity product for cardiology environments.
Waterloo, Ontario-based Mitra chose to base the U.S. company in Hartland due to its close proximity to area universities as well as several cardiology vendors, such as Camtronics Medical Systems, GE Medical Systems, and Marquette Medical Systems.
The U.S. company will join another Mitra subsidiary, Mitra ApS of Copenhagen, Denmark, which was launched in July.
Mitra also has received Food and Drug Administration 510(k) clearance for Image Vault, a Windows NT-based archiving software offering. Targeted primarily at cardiology, the DICOM-compliant Image Vault stores images on standard magnetic tapes, and has the ability to send, receive, display, store, and archive DICOM non-compressed and JPEG-compressed images. Image Vault, which is scalable, can also read/write a collection of images to and from CD-R media in a method defined by DICOM, according to the firm.
Image Vault is not the first archive offering developed by Mitra. The company developed a Unix-based product for radiology in an exclusive relationship with Agfa. That exclusive agreement applies only to radiology archiving, however, and Mitra anticipates that multiple firms will be accessing Image Vault in the cardiology realm, said Eric Peterson, president.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).